NCT04546841View on ClinicalTrials.gov

Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

December 2, 2021

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

multipeptide cocktail

"Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening"

Trial Locations (1)

72076

University Hospital Tuebingen, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER

NCT04546841 - Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults | Biotech Hunter | Biotech Hunter